Weikang Bio-Technology (WKBT.OB) Reiterates Fiscal 2010 Revenue Guidance of $55 Million and Net Profit of $21 Million
Yesterday, Weikang Bio-Technology released a statement targeting 2011 revenue growth to be 30% to 50% over 2010 revenue. The Chinese developer and manufacturer of traditional Chinese medicine products, Western prescription and over the counter pharmaceuticals and related health products also announced a 2010 revenue guidance of $55 million, a net profit of $21 million and earnings per share of $0.75. The company expects stockholders' equity to be $1.71 per share ($48 million). Weikang is preparing to launch five new therapeutics - two in the fourth quarter of 2010 and three in the first quarter of 2011. These are expected to…